Gilead Sciences, Inc. (GILD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: November 18, 2014
Pages: 137
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G571002D1F1EN
Leaflet:

Download PDF Leaflet

Gilead Sciences, Inc. (GILD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company. The company undertakes the discovery, development and commercialization of innovative medicines in areas of unmet medical need. The product and pipeline portfolio of the company focuses on various therapeutic areas including human immunodeficiency virus/ auto immunodeficiency syndrome (HIV/AIDS), liver, cardiovascular, respiratory, inflammation and oncology. Gilead undertakes the US and international operations, with more than 40 marketing subsidiaries in the Czech Republic, Denmark, Finland, France, Australia, Austria, Belgium and Canada, among others. It operates in Europe, North America and South America and Asia-Pacific. The company continues to add to its existing portfolio of products through its internal discovery and clinical development programs and through a product acquisition and in-licensing strategy. Gilead is headquartered in Foster City, California, the US.

Gilead Sciences, Inc. (GILD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Gilead Sciences, Inc., Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Gilead Sciences, Inc., Medical Devices Deals, 2008 to YTD 2014
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Purchase
Gilead Sciences Completes Acquisition Of Oceanside Clinical Plant From Genentech For US$28.3 Million
Partnerships
Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences
Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa
Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services
AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery
Adimab Enters Into Co-Development Agreement With Gilead Sciences
Gilead Sciences Enters Into Research Collaboration With Yale School of Medicine
Bioanalytical Systems Enters Into An Agreement With Pharmasset
Selcia Enters Into Collaboration With Gilead Sciences
YM BioSciences Enters Into Collaboration Agreement With National Research Council Of Canada
Gilead Sciences Enter Into An Agreement With Merck
Gilead Sciences Enters Into Research Collaboration With Gladstone Institute
Merger
Cytopia Merges With YM BioSciences
Licensing Agreements
Gilead Sciences Enters into Licensing Agreement with Cadila Healthcare
Gilead Sciences Enters into Licensing Agreement with Cipla
Gilead Sciences Enters into Licensing Agreement with Hetero Labs
Gilead Sciences Enters into Licensing Agreement with Mylan Labs
Gilead Sciences Enters into Licensing Agreement with Ranbaxy Labs
Gilead Sciences Enters into Licensing Agreement with SeQuent Scientific
Gilead Sciences Enters into Licensing Agreement with Strides Arcolab
Theraclone Sciences Enters into Licensing Agreement with Gilead Sciences
Parion Sciences Enters Into Licensing Agreement With Gilead Sciences
Gilead Sciences Enters Into Licensing Agreement With CURx Pharma
Shilpa Medicare Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences For HIV Drugs
Shasun Pharma Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences
MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology
Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine
Ranbaxy Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine
Strides Arcolab Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine
Japan Tobacco Enters Into Licensing Agreement With Gilead Sciences For cobicistat
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma
Bristol-Myers Squibb Enters Into Licensing Agreement With Gilead Sciences
Gilead Sciences Enters Into Licensing Agreement With GlobeImmune
Boehringer Ingelheim Enters Into Licensing Agreement With Gilead Sciences For BI 224436
Gilead Sciences Extends Licensing Agreement With Hetero Drugs For Tenofovir, Elvitegravir, Cobicistat And Quad
Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad
Gilead Sciences Extends Licensing Agreement With Ranbaxy Labs For Tenofovir, Elvitegravir, Cobicistat And Quad
Gilead Sciences Extends Licensing Agreement With Strides Arcolab For Tenofovir, Elvitegravir, Cobicistat And Quad
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma
Gilead Sciences Enters Into Licensing And Collaboration Agreement With MicroDose For MDT-637
Yuhan Enters Into Licensing Agreement With Gilead Sciences For Viread
VetDC Enters Into Licensing Agreement With Gilead Sciences For GS 9219
GlaxoSmithKline Enters Into Licensing Agreement With Gilead Sciences
Achillion Pharma Amends Co-Development Agreement With Gilead Sciences
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma
Equity Offering
YM BioSciences Completes Public Offering Of Common Stock For US$80 Million
Pharmasset Completes Public Offering For US$129.5 Million
YM BioSciences Completes Underwritten Public Offering Of US$46 Million
YM BioSciences Completes Private Placement Of US$3.2 Million
Pharmasset Announces Exercise Of Underwriters’ Overallotment Option For US$107 Million
YM BioSciences Completes Registered Direct Offering Of Units For US$17.5 Million
Pharmasset Completes Public Offering Of Its Common Stock For US$34 Million
Pharmasset Completes Registered Direct Offering Of US$46 Million
Pharmasset Completes Registered Direct Public Offering Of US$26 Million
Debt Offering
Gilead Sciences Prices Public Offering of 2.35% Notes Due 2020 for USD500 Million
Gilead Sciences Prices Public Offering of 3.5% Notes Due 2025 for USD1.75 Billion
Gilead Sciences Prices Public Offering of 4.5% Notes Due 2045 for USD1.75 Billion
Gilead Sciences Completes Public Offering Of Notes Due 2019 For US$500 Million
Gilead Sciences Completes Public Offering Of Notes Due 2024 For US$1.75 Billion
Gilead Sciences Completes Public Offering Of Notes Due 2044 For US$1.75 Billion
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$750 Million
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2016 For US$700 Million
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2021 For US$1.25 Billion
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2041 For US$1 Billion
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2021 For US$1,000 Million
Gilead Sciences Completes Private Placement Of 1% Senior Notes For US$1,100 Million
Gilead Sciences Completes Private Placement Of 1.625% Senior Notes For US$1,100 Million
Asset Transactions
Galen Acquires DaunoXome, Chemotherapy Agent, From Gilead Sciences
Graceway Pharma Acquires Licensing Rights From Gilead Sciences
Acquisition
Gilead Sciences Completes Acquisition Of YM BioSciences, Drug Development Company
Gilead Sciences Completes Acquisition Of Pharmasset For US$11.2 Billion
Gilead Sciences Acquires Calistoga Pharma
Gilead Sciences Acquires Arresto Biosciences
Gilead Sciences Acquires CGI Pharma
Gilead Sciences Acquires CV Therapeutics
Gilead Sciences Acquires Navitas Assets
Gilead Sciences, Inc. - Key Competitors
Key Employees
Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Key Facts, 2013
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Gilead Sciences, Inc., Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Gilead Sciences, Inc., Deals By Therapy Area, 2008 to YTD 2014
Gilead Sciences, Inc., Medical Devices Deals, 2008 to YTD 2014
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014
Gilead Sciences Completes Acquisition Of Oceanside Clinical Plant From Genentech For US$28.3 Million
Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences
Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa
Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services
AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery
Adimab Enters Into Co-Development Agreement With Gilead Sciences
Gilead Sciences Enters Into Research Collaboration With Yale School of Medicine
Bioanalytical Systems Enters Into An Agreement With Pharmasset
Selcia Enters Into Collaboration With Gilead Sciences
YM BioSciences Enters Into Collaboration Agreement With National Research Council Of Canada
Gilead Sciences Enter Into An Agreement With Merck
Gilead Sciences Enters Into Research Collaboration With Gladstone Institute
Cytopia Merges With YM BioSciences
Gilead Sciences Enters into Licensing Agreement with Cadila Healthcare
Gilead Sciences Enters into Licensing Agreement with Cipla
Gilead Sciences Enters into Licensing Agreement with Hetero Labs
Gilead Sciences Enters into Licensing Agreement with Mylan Labs
Gilead Sciences Enters into Licensing Agreement with Ranbaxy Labs
Gilead Sciences Enters into Licensing Agreement with SeQuent Scientific
Gilead Sciences Enters into Licensing Agreement with Strides Arcolab
Theraclone Sciences Enters into Licensing Agreement with Gilead Sciences
Parion Sciences Enters Into Licensing Agreement With Gilead Sciences
Gilead Sciences Enters Into Licensing Agreement With CURx Pharma
Shilpa Medicare Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences For HIV Drugs
Shasun Pharma Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences
MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology
Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine
Ranbaxy Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine
Strides Arcolab Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine
Japan Tobacco Enters Into Licensing Agreement With Gilead Sciences For cobicistat
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma
Bristol-Myers Squibb Enters Into Licensing Agreement With Gilead Sciences
Gilead Sciences Enters Into Licensing Agreement With GlobeImmune
Boehringer Ingelheim Enters Into Licensing Agreement With Gilead Sciences For BI 224436
Gilead Sciences Extends Licensing Agreement With Hetero Drugs For Tenofovir, Elvitegravir, Cobicistat And Quad
Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad
Gilead Sciences Extends Licensing Agreement With Ranbaxy Labs For Tenofovir, Elvitegravir, Cobicistat And Quad
Gilead Sciences Extends Licensing Agreement With Strides Arcolab For Tenofovir, Elvitegravir, Cobicistat And Quad
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma
Gilead Sciences Enters Into Licensing And Collaboration Agreement With MicroDose For MDT-637
Yuhan Enters Into Licensing Agreement With Gilead Sciences For Viread
VetDC Enters Into Licensing Agreement With Gilead Sciences For GS 9219
GlaxoSmithKline Enters Into Licensing Agreement With Gilead Sciences
Achillion Pharma Amends Co-Development Agreement With Gilead Sciences
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma
YM BioSciences Completes Public Offering Of Common Stock For US$80 Million
Pharmasset Completes Public Offering For US$129.5 Million
YM BioSciences Completes Underwritten Public Offering Of US$46 Million
YM BioSciences Completes Private Placement Of US$3.2 Million
Pharmasset Announces Exercise Of Underwriters’ Overallotment Option For US$107 Million
YM BioSciences Completes Registered Direct Offering Of Units For US$17.5 Million
Pharmasset Completes Public Offering Of Its Common Stock For US$34 Million
Pharmasset Completes Registered Direct Offering Of US$46 Million
Pharmasset Completes Registered Direct Public Offering Of US$26 Million
Gilead Sciences Prices Public Offering of 2.35% Notes Due 2020 for USD500 Million
Gilead Sciences Prices Public Offering of 3.5% Notes Due 2025 for USD1.75 Billion
Gilead Sciences Prices Public Offering of 4.5% Notes Due 2045 for USD1.75 Billion
Gilead Sciences Completes Public Offering Of Notes Due 2019 For US$500 Million
Gilead Sciences Completes Public Offering Of Notes Due 2024 For US$1.75 Billion
Gilead Sciences Completes Public Offering Of Notes Due 2044 For US$1.75 Billion
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$750 Million
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2016 For US$700 Million
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2021 For US$1.25 Billion
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2041 For US$1 Billion
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2021 For US$1,000 Million
Gilead Sciences Completes Private Placement Of 1% Senior Notes For US$1,100 Million
Gilead Sciences Completes Private Placement Of 1.625% Senior Notes For US$1,100 Million
Galen Acquires DaunoXome, Chemotherapy Agent, From Gilead Sciences
Graceway Pharma Acquires Licensing Rights From Gilead Sciences
Gilead Sciences Completes Acquisition Of YM BioSciences, Drug Development Company
Gilead Sciences Completes Acquisition Of Pharmasset For US$11.2 Billion
Gilead Sciences Acquires Calistoga Pharma
Gilead Sciences Acquires Arresto Biosciences
Gilead Sciences Acquires CGI Pharma
Gilead Sciences Acquires CV Therapeutics
Gilead Sciences Acquires Navitas Assets
Gilead Sciences, Inc., Key Competitors
Gilead Sciences, Inc., Key Employees
Gilead Sciences, Inc., Other Locations
Gilead Sciences, Inc., Subsidiaries

LIST OF FIGURES

Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014
Gilead Sciences, Inc., Medical Devices Deals, 2008 to YTD 2014
Skip to top


Ask Your Question

Gilead Sciences, Inc. (GILD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: